https://www.selleckchem.com/products/ltgo-33.html
0, = .006). Overall survival was 61% in the SIC + IVIG and 38% in the SIC only group (odds ratio 2.2, 95% confidence interval 0.9-5.4, = .091 after controlling for baseline imbalances). IVIG significantly prolonged median survival time (68 versus 18 days, = .014) and significantly reduced plasma levels of C-reactive protein (median change from baseline -71.5 versus -0.3 mg/L, = .049). Clinically relevant benefits through adjunct IVIG treatment in COVID-19 need to be confirmed in a randomized, controlled trial. Clinically relevant be
Like
Comment
Share
